We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03610971
Recruitment Status : Recruiting
First Posted : August 1, 2018
Last Update Posted : January 3, 2023
H. Jean Khoury Cure CML Consortium
Incyte Corporation
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute

Brief Summary:
The purpose of this study is to determine if adding Ruxolitinib to a Tyrone Kinase Inhibitor (TKI), prior to a second attempt at stopping a TKI will lead to prolonged treatment free remission (TFR).

Condition or disease Intervention/treatment Phase
Chronic Phase Chronic Myeloid Leukemia Chronic Myeloid Leukemia, Chronic Phase Drug: Ruxolitinib Drug: BCR-ABL Tyrosine Kinase Inhibitor (TKI) Phase 2

Detailed Description:

All participants will have a confirmed diagnosis of chronic phase chronic myeloid leukemia (CML) and must have previously attempted to discontinue TKI therapy. All participants must be restarted on a TKI at the time of relapse in order to be eligible for this trial.

After completion of 12 cycles of combination therapy, eligible participants will remain in the TFR phase of the study for up to 36 months, and will have central polymerase chain reaction (PCR) testing during the first 24 months. Therefore, the total duration of the trial will be approximately 48 months (12 months on combination treatment phase + 36 months in the TFR phase).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 51 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Actual Study Start Date : November 19, 2019
Estimated Primary Completion Date : January 2024
Estimated Study Completion Date : January 2024

Arm Intervention/treatment
Experimental: Combination Therapy + Remission Phase

Combination therapy followed by treatment free remission (TFR) phase.

Combination Therapy: Ruxolitinib plus BCR-ABL Tyrosine Kinase Inhibitors (TKIs).

All eligible patients will begin ruxolitinib in combination with their BCR-ABL TKI on cycle 1 day 1 of the combination phase. For cycle 2 and beyond, if day 1 of a cycle is delayed, day 1 procedures should be repeated if out of the specified window and day 1 of the cycle is considered the day study drug is restarted. They will continue combination therapy for a total of 12 cycles. Each cycle will be approximately 28 days.

At the end of 12 cycles ruxolitinib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, participants will discontinue their BCR-ABL TKI and be monitored off treatment.

Drug: Ruxolitinib
Ruxolitinib: 15 mg by mouth (PO) twice a day (BID).
Other Name: Jakafi®

Drug: BCR-ABL Tyrosine Kinase Inhibitor (TKI)
The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.
Other Name: TKI

Primary Outcome Measures :
  1. 12 Month Treatment Free Remission (TFR) [ Time Frame: 12 months ]
    TFR rate after completion of 12 cycles of combination therapy.

Secondary Outcome Measures :
  1. Adverse Events Possibly Related to Study Treatment [ Time Frame: Up to 30 days post treatment, approximately 13 months per participant ]
    Establish the adverse event profile of ruxolitinib in combination with BCR-ABL TKIs: Adverse Events (AEs) and Serious Adverse Events (SAEs) according to Common Terminology Criteria for Adverse Events (CTCAE) V5.0, that are possibly, probably, or definitely related to study treatment.

Other Outcome Measures:
  1. Incidence of Improved Scores in Health Related Quality of Life Questionnaire [ Time Frame: Up to 48 months ]
    Number of participants with an improved score in 2 or more categories of the questionnaire at the end of the TFR phase, when compared to the score for the same questions when completed at the end of 12 cycles of combination therapy.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Willing and able to give informed consent
  • Diagnosed with CML in chronic phase and have either the b3a2 (e14a2) or b2a2 (e13a2) variants that give rise to the p210 BCR-ABL protein.
  • Must have a documented history of attempting only one prior TKI discontinuation under the guidance of a treating physician
  • Must have met ALL the following criteria prior to first attempt to discontinue their TKI:

    • Stable molecular response (MR4; <0.01% IS) for > 2 years, as documented on at least 4 tests, performed at least 3 months apart
    • Treatment with one of the following FDA approved TKI; imatinib, dasatinib, nilotinib or bosutinib, at any dose for a minimum of 3 years prior to discontinuing TKIs
    • Has been on any number of TKIs, but has not been resistant to any TKI (changes made for intolerance are allowed)
  • Must have relapsed (defined as loss of major molecular response (MMR), RQ-PCR for BCR-ABL > 0.1% IS after first attempted discontinuation of TKI
  • After first failed TFR attempt, must have a minimum duration of 1 year on a TKI, and must plan to remain on this same TKI for a minimum of 12 months during the combination treatment phase
  • Current TKI must be the same as the TKI being taken prior to the initial TFR attempt (e.g., if patient is on imatinib prior to first TFR attempt, they should be on imatinib at time of enrollment on this study)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-3
  • Must have a RQ-PCR for BCR-ABL less than 0.01% IS reported by the trial designated central lab at time of study enrollment
  • Must adhere to all study contraception guidelines

Exclusion Criteria:

  • History of accelerated or blast phase CML
  • History of TKI resistance
  • A second malignancy requiring active treatment
  • Have previously received treatment with a JAK inhibitor.
  • Platelet count less than 100 × 10^9/L or an absolute neutrophil count of less than 1 × 10^9/L or Hemoglobin less than 8 g/dL
  • AST and ALT ≥ 3 times the institutional upper limit of normal (ULN)
  • Creatinine ≥ 2 times ULN
  • Total bilirubin ≥ 1.5 times ULN (unless direct bilirubin is within normal limits)
  • Pregnant or lactating
  • Unable to comply with lab appointments schedule and patient response outcome assessments
  • Another investigational drug within 4 weeks of enrollment
  • Any serious medical or psychiatric illness that could, in the investigator's opinion, interfere with the completion of treatment according to this protocol
  • Have undergone a prior allogeneic transplant
  • Screening 12-lead ECG showing a baseline corrected QT interval >500msec (patients with a pacemaker will still be eligible with QTc>500msec)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03610971

Layout table for location information
United States, Florida
H. Lee Moffitt Cancer Center and Research Institute Recruiting
Tampa, Florida, United States, 33612
Contact: Christine Ternival    813-745-2146    Christine.Ternival@moffitt.org   
Contact: Kendra Sweet, M.D.    813-745-8986    kendra.sweet@moffitt.org   
Principal Investigator: Kendra Sweet, M.D.         
United States, Georgia
Emory -Winship Cancer Institute Not yet recruiting
Atlanta, Georgia, United States, 30322
Contact: Rebecca Klisovic, MD    404-778-1900    Rebecca.Klisovic@emoryhealthcare.org   
Principal Investigator: Rebecca Klisovic, MD         
United States, New Jersey
Memorial Sloan Kettering - Bergen Recruiting
Montvale, New Jersey, United States, 07645
Contact: Michael Mauro, MD    646-608-3744    MauroM@mskcc.org   
United States, New York
Roswell Park Comprehensive Cancer Center Recruiting
Buffalo, New York, United States, 14263
Contact: James Thompson, MD    716-845-2300    James.Thompson@roswellpark.org   
Principal Investigator: James Thompson, MD         
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Recruiting
New York, New York, United States, 10021
Contact: Michael Mauro, MD    646-608-3744    MauroM@mskcc.org   
United States, Oregon
Oregon Health & Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Michael Heinrich, MD    503-494-1080    trials@ohsu.edu   
United States, Washington
Fred Hutchinson Cancer Research Center Recruiting
Seattle, Washington, United States, 98109
Contact: Vivian Oehler, MD    206-667-1340    VOehler@u.washington.edu   
Principal Investigator: Vivian Oehler, MD         
United States, Wisconsin
Froedtert Hospital & the Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Ehab Atallah, MD    414-805-4600    eatallah@mcw.edu   
Principal Investigator: Ehab Atallah, MD         
Sponsors and Collaborators
H. Lee Moffitt Cancer Center and Research Institute
H. Jean Khoury Cure CML Consortium
Incyte Corporation
Layout table for investigator information
Principal Investigator: Kendra Sweet, M.D. H. Lee Moffitt Cancer Center and Research Institute
Additional Information:
Layout table for additonal information
Responsible Party: H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier: NCT03610971    
Other Study ID Numbers: MCC-19660
HJKC3-0002 ( Other Identifier: H. Jean Khoury Cure CML Consortium )
First Posted: August 1, 2018    Key Record Dates
Last Update Posted: January 3, 2023
Last Verified: December 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by H. Lee Moffitt Cancer Center and Research Institute:
Chronic Myeloid Leukemia
combination therapy
BCR-ABL oncogene
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic-Phase
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases